Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of the first 3,000 patients

Takao Koike, Masayoshi Harigai, Naoki Ishiguro, Shigeko Inokuma, Shuji Takei, Tsutomu Takeuchi, Hisashi Yamanaka, Yoshiya Tanaka

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

This interim analysis of postmarketing surveillance data for adalimumab-treated rheumatoid arthritis (RA) patients summarizes safety and effectiveness during the first 24 weeks of therapy for the first 3,000 patients treated in Japan (June 2008-December 2009). Patient eligibility for antitumor necrosis factor therapy was based on the Japanese College of Rheumatology treatment guidelines and Japanese labeling. All patients were screened for tuberculosis. Approximately 50% of the population was biologic näve, 66% received concomitant methotrexate (MTX), and 72% received concomitant glucocorticoids. The overall incidence rate of adverse events was 31% (5.5% serious) and that of adverse drug reactions (ADRs) was 27% (4.1% serious). Incidence rates of ADRs and serious ADRs were similar regardless of prior biologic therapy or concomitant MTX use but were significantly higher in patients receiving glucocorticoids compared with those not receiving glucocorticoids. Bacterial/bronchial pneumonia occurred in 1.2% of patients; Interstitial pneumonia, 0.6%; Pneumocystis jirovecii pneumonia, 0.3%; tuberculosis, 0.13%; and administration-site reactions, 6.1%. Mean 28-joint Disease Activity Scores decreased significantly after 24 weeks from 5.29 to 3.91. All subgroups showed significant improvement, particularly the biologic-naïve patients receiving concomitant MTX. No new safety concerns were identified. ADR Incidence rates were similar to those of other biologic agents approved for RA.

Original languageEnglish
Pages (from-to)498-508
Number of pages11
JournalModern Rheumatology
Volume22
Issue number4
DOIs
Publication statusPublished - 2012 Aug

Fingerprint

Rheumatoid Arthritis
Drug-Related Side Effects and Adverse Reactions
Safety
Methotrexate
Glucocorticoids
Incidence
Tuberculosis
Bacterial Pneumonia
Pneumocystis carinii
Bronchopneumonia
Biological Therapy
Pneumocystis Pneumonia
Joint Diseases
Interstitial Lung Diseases
Biological Factors
Rheumatology
Patient Safety
Biological Products
Adalimumab
Japan

Keywords

  • Adalimumab
  • Effectiveness
  • Postmarketing surveillance
  • Rheumatoid arthritis
  • Safety

ASJC Scopus subject areas

  • Rheumatology

Cite this

Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients : Postmarketing surveillance report of the first 3,000 patients. / Koike, Takao; Harigai, Masayoshi; Ishiguro, Naoki; Inokuma, Shigeko; Takei, Shuji; Takeuchi, Tsutomu; Yamanaka, Hisashi; Tanaka, Yoshiya.

In: Modern Rheumatology, Vol. 22, No. 4, 08.2012, p. 498-508.

Research output: Contribution to journalArticle

Koike, Takao ; Harigai, Masayoshi ; Ishiguro, Naoki ; Inokuma, Shigeko ; Takei, Shuji ; Takeuchi, Tsutomu ; Yamanaka, Hisashi ; Tanaka, Yoshiya. / Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients : Postmarketing surveillance report of the first 3,000 patients. In: Modern Rheumatology. 2012 ; Vol. 22, No. 4. pp. 498-508.
@article{4e8de7eae5a44ec599e8df5cf3637ad2,
title = "Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of the first 3,000 patients",
abstract = "This interim analysis of postmarketing surveillance data for adalimumab-treated rheumatoid arthritis (RA) patients summarizes safety and effectiveness during the first 24 weeks of therapy for the first 3,000 patients treated in Japan (June 2008-December 2009). Patient eligibility for antitumor necrosis factor therapy was based on the Japanese College of Rheumatology treatment guidelines and Japanese labeling. All patients were screened for tuberculosis. Approximately 50{\%} of the population was biologic n{\"a}ve, 66{\%} received concomitant methotrexate (MTX), and 72{\%} received concomitant glucocorticoids. The overall incidence rate of adverse events was 31{\%} (5.5{\%} serious) and that of adverse drug reactions (ADRs) was 27{\%} (4.1{\%} serious). Incidence rates of ADRs and serious ADRs were similar regardless of prior biologic therapy or concomitant MTX use but were significantly higher in patients receiving glucocorticoids compared with those not receiving glucocorticoids. Bacterial/bronchial pneumonia occurred in 1.2{\%} of patients; Interstitial pneumonia, 0.6{\%}; Pneumocystis jirovecii pneumonia, 0.3{\%}; tuberculosis, 0.13{\%}; and administration-site reactions, 6.1{\%}. Mean 28-joint Disease Activity Scores decreased significantly after 24 weeks from 5.29 to 3.91. All subgroups showed significant improvement, particularly the biologic-na{\"i}ve patients receiving concomitant MTX. No new safety concerns were identified. ADR Incidence rates were similar to those of other biologic agents approved for RA.",
keywords = "Adalimumab, Effectiveness, Postmarketing surveillance, Rheumatoid arthritis, Safety",
author = "Takao Koike and Masayoshi Harigai and Naoki Ishiguro and Shigeko Inokuma and Shuji Takei and Tsutomu Takeuchi and Hisashi Yamanaka and Yoshiya Tanaka",
year = "2012",
month = "8",
doi = "10.1007/s10165-011-0541-5",
language = "English",
volume = "22",
pages = "498--508",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients

T2 - Postmarketing surveillance report of the first 3,000 patients

AU - Koike, Takao

AU - Harigai, Masayoshi

AU - Ishiguro, Naoki

AU - Inokuma, Shigeko

AU - Takei, Shuji

AU - Takeuchi, Tsutomu

AU - Yamanaka, Hisashi

AU - Tanaka, Yoshiya

PY - 2012/8

Y1 - 2012/8

N2 - This interim analysis of postmarketing surveillance data for adalimumab-treated rheumatoid arthritis (RA) patients summarizes safety and effectiveness during the first 24 weeks of therapy for the first 3,000 patients treated in Japan (June 2008-December 2009). Patient eligibility for antitumor necrosis factor therapy was based on the Japanese College of Rheumatology treatment guidelines and Japanese labeling. All patients were screened for tuberculosis. Approximately 50% of the population was biologic näve, 66% received concomitant methotrexate (MTX), and 72% received concomitant glucocorticoids. The overall incidence rate of adverse events was 31% (5.5% serious) and that of adverse drug reactions (ADRs) was 27% (4.1% serious). Incidence rates of ADRs and serious ADRs were similar regardless of prior biologic therapy or concomitant MTX use but were significantly higher in patients receiving glucocorticoids compared with those not receiving glucocorticoids. Bacterial/bronchial pneumonia occurred in 1.2% of patients; Interstitial pneumonia, 0.6%; Pneumocystis jirovecii pneumonia, 0.3%; tuberculosis, 0.13%; and administration-site reactions, 6.1%. Mean 28-joint Disease Activity Scores decreased significantly after 24 weeks from 5.29 to 3.91. All subgroups showed significant improvement, particularly the biologic-naïve patients receiving concomitant MTX. No new safety concerns were identified. ADR Incidence rates were similar to those of other biologic agents approved for RA.

AB - This interim analysis of postmarketing surveillance data for adalimumab-treated rheumatoid arthritis (RA) patients summarizes safety and effectiveness during the first 24 weeks of therapy for the first 3,000 patients treated in Japan (June 2008-December 2009). Patient eligibility for antitumor necrosis factor therapy was based on the Japanese College of Rheumatology treatment guidelines and Japanese labeling. All patients were screened for tuberculosis. Approximately 50% of the population was biologic näve, 66% received concomitant methotrexate (MTX), and 72% received concomitant glucocorticoids. The overall incidence rate of adverse events was 31% (5.5% serious) and that of adverse drug reactions (ADRs) was 27% (4.1% serious). Incidence rates of ADRs and serious ADRs were similar regardless of prior biologic therapy or concomitant MTX use but were significantly higher in patients receiving glucocorticoids compared with those not receiving glucocorticoids. Bacterial/bronchial pneumonia occurred in 1.2% of patients; Interstitial pneumonia, 0.6%; Pneumocystis jirovecii pneumonia, 0.3%; tuberculosis, 0.13%; and administration-site reactions, 6.1%. Mean 28-joint Disease Activity Scores decreased significantly after 24 weeks from 5.29 to 3.91. All subgroups showed significant improvement, particularly the biologic-naïve patients receiving concomitant MTX. No new safety concerns were identified. ADR Incidence rates were similar to those of other biologic agents approved for RA.

KW - Adalimumab

KW - Effectiveness

KW - Postmarketing surveillance

KW - Rheumatoid arthritis

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84865376327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865376327&partnerID=8YFLogxK

U2 - 10.1007/s10165-011-0541-5

DO - 10.1007/s10165-011-0541-5

M3 - Article

C2 - 21993918

AN - SCOPUS:84865376327

VL - 22

SP - 498

EP - 508

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 4

ER -